<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: One of the main causes of mortality and morbidity following <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> (SAH) is the development of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, a frequent complication arising in the weeks after the initial <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite extensive research, to date no effective treatment of vasospasm exists </plain></SENT>
<SENT sid="2" pm="."><plain>Prostacyclin is a potent <z:chebi fb="1" ids="35620">vasodilator</z:chebi> and inhibitor of platelet aggregation </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro models have shown a relaxing effect of prostacyclin after induced contraction in cerebral arteries, and a recent pilot trial showed a positive effect on <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in a clinical setting </plain></SENT>
<SENT sid="4" pm="."><plain>No randomised, clinical trials have been conducted, investigating the possible pharmacodynamic effects of prostacyclin on the human brain following SAH </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: This trial is a single-centre, randomised, placebo-controlled, parallel group, blinded, clinical, pilot trial </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 90 patients with SAH will be randomised to one of three intervention arms: epoprostenol 1 ng/kg/min, epoprostenol 2 ng/kg/min or placebo in addition to standard treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Trial medication will start day 5 after SAH and continue to day 10 </plain></SENT>
<SENT sid="8" pm="."><plain>The primary outcome measure is changes in regional cerebral blood flow from baseline in the arterial territories of the anterior cerebral artery, medial cerebral artery and the posterior cerebral artery, measured by CT perfusion scan </plain></SENT>
<SENT sid="9" pm="."><plain>The secondary outcomes will be vasospasm measured by CT angiography, ischaemic parameters measured by brain microdialysis, flow velocities in the medial cerebral artery, clinical parameters and outcome (Glasgow Outcome Scale) at 3 months </plain></SENT>
<SENT sid="10" pm="."><plain>TRIAL REGISTRATION: Clinicaltrials.gov NCT01447095 </plain></SENT>
</text></document>